Annette Oxenius

Prof. Annette Oxenius

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2004 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PWPetra Wolint
Petra Wolint
MBMichael R. Betts
Michael R. Betts
RKRichard A. Koup
Richard A. Koup
AOAnnette Oxenius
Annette Oxenius
CD8+ T cells play a central role in the resolution and containment of viral infections. A key effector function of CD8+ T cells is their cytolytic activity toward infected cells. Here, we studied the regulation of cytolytic activity in naive, effector, and central versus effector memory CD8+ T cells specific for the same glycoprotein-derived epitope of lymphocytic choriomeningitis virus. Our results show that the kinetics of degranulation, assessed by a novel flow cytometric based assay, were identical in effector and both subsets of memory CD8+ T cells, but absent in naive CD8+ T cells. However, immediate cytolytic activity was most pronounced in effector T cells, low in effector memory T cells, and absent in central memory T cells, correlating with the respective levels of cytolytic effector molecules present in lytic granules. These results indicate that an inherent program of degranulation is a feature of antigen-experienced cells as opposed to naive CD8+ T cells and that the ability of CD8+ T cells to induce target cell apoptosis/death is dependent on granule protein content rather than on the act of degranulation itself. Furthermore, these results provide a potential mechanism by which central memory CD8+ T cell–mediated death of antigen-presenting cells within the lymph node is avoided.

27 May 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DZDietmar Zehn
Dietmar Zehn
RTRobert Thimme
Robert Thimme
ELEnrico Lugli
Enrico Lugli
GAGustavo Pereira de Almeida
Gustavo Pereira de Almeida
AOAnnette Oxenius
Annette Oxenius

1 October 2005 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MBMartin F. Bachmann
Martin F. Bachmann
PWPetra Wolint
Petra Wolint
KSKatrin Schwarz
Katrin Schwarz
PJPetra JägEr
Petra JägEr
AOAnnette Oxenius
Annette Oxenius
Three major subsets of Ag-experienced CD8+ T cells have been identified according to their expression of CD62L and CD127. These markers are associated with central memory T cells (CD62L+CD127+), effector memory T cells (CD162L−CD127+), and effector T cells (CD62L−CD127−). In this study we characterized the development of these three populations during acute and chronic viral infections and after immunization with virus-like particles and determined their lineage relation and functional and protective properties. We found that the balance between the three subsets was critically regulated by the availability of Ag and time. After initial down-regulation of CD127, the responding CD8+ T cell population down-regulated CD62L and re-expressed CD127. Dependent on Ag availability, the cells then further differentiated into CD62L−CD127− effector cells or, in the absence of Ag, re-expressed CD62L to become central memory T cells. Although all three populations efficiently produced effector cytokines such as IFN-γ, CD62L−CD127− effector cells exhibited the highest ex vivo lytic potential. In contrast, CD62L+CD127+ central memory T cells most efficiently produced IL-2 and proliferated extensively in vitro and in vivo upon antigenic restimulation. Strikingly, only effector and effector memory, but not central memory, T cells were able to protect against peripheral infection with vaccinia virus, whereas central memory T cells were most potent at protecting against systemic infection with lymphocytic choriomeningitis virus, indicating that the antiviral protective capacities of specific CD8+ T cell subsets are closely related to the nature of the challenging pathogen.

1 June 2014 in Immunity
Verified
Journal Article
Closed access
JCJosh Crouse
Josh Crouse
GBGregor Bedenikovic
Gregor Bedenikovic
MWMelanie Wiesel
Melanie Wiesel
MIMark Ibberson
Mark Ibberson
IXIoannis Xenarios
Ioannis Xenarios
AOAnnette Oxenius
Annette Oxenius

10 December 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HFHelge Frebel
Helge Frebel
VNVeronika Nindl
Veronika Nindl
RSReto A. Schuepbach
Reto A. Schuepbach
TBThomas Braunschweiler
Thomas Braunschweiler
KRKirsten Richter
Kirsten Richter
AOAnnette Oxenius
Annette Oxenius
The inhibitory programmed death 1 (PD-1)–programmed death ligand 1 (PD-L1) pathway contributes to the functional down-regulation of T cell responses during persistent systemic and local virus infections. The blockade of PD-1–PD-L1–mediated inhibition is considered as a therapeutic approach to reinvigorate antiviral T cell responses. Yet previous studies reported that PD-L1–deficient mice develop fatal pathology during early systemic lymphocytic choriomeningitis virus (LCMV) infection, suggesting a host protective role of T cell down-regulation. As the exact mechanisms of pathology development remained unclear, we set out to delineate in detail the underlying pathogenesis. Mice deficient in PD-1–PD-L1 signaling or lacking PD-1 signaling in CD8 T cells succumbed to fatal CD8 T cell–mediated immunopathology early after systemic LCMV infection. In the absence of regulation via PD-1, CD8 T cells killed infected vascular endothelial cells via perforin-mediated cytolysis, thereby severely compromising vascular integrity. This resulted in systemic vascular leakage and a consequential collapse of the circulatory system. Our results indicate that the PD-1–PD-L1 pathway protects the vascular system from severe CD8 T cell–mediated damage during early systemic LCMV infection, highlighting a pivotal physiological role of T cell down-regulation and suggesting the potential development of immunopathological side effects when interfering with the PD-1–PD-L1 pathway during systemic virus infections.

1 December 2021 in Trends in Immunology
Verified
Journal Article
Open access
APAlessandro Pedrioli
Alessandro Pedrioli
AOAnnette Oxenius
Annette Oxenius
Monoclonal antibodies (mAbs) are often selected from antigen-specific single B cells derived from different hosts, which are notably short-lived in ex vivo culture conditions and hence, arduous to interrogate. The development of several new techniques and protocols has facilitated the isolation and retrieval of antibody-coding sequences of antigen-specific B cells by also leveraging miniaturization of reaction volumes. Alternatively, mAbs can be generated independently of antigen-specific B cells, comprising display technologies and, more recently, artificial intelligence-driven algorithms. Consequently, a considerable variety of techniques are used, raising the demand for better consolidation. In this review, we present and discuss the major techniques available to interrogate antigen-specific single B cells to isolate antigen-specific mAbs, including their main advantages and disadvantages.